Hypoglycemic energy failure

In diabetes with recurrent substantial hypoglycemia, local fuel deprivation causes irreversible loss of peptidergic C-fiber terminals rather than only transient electrical failure.

Scope: Exposure-defined exception: people with diabetes experiencing recurrent or prolonged hypoglycemia, often during glucose-lowering treatment. Materiality uses the five-year, 20% preservation criterion within an identifiable subgroup accounting for at least 10% of neuropathy cases in this exposed population, not all type 2 diabetes. No particular CGM threshold is asserted to be a proven injury threshold.

Causal role: treatment-associated metabolic second insult. Unless the scope specifies an exception, materiality means at least 20% less five-year net terminal loss in an identifiable subgroup representing at least 10% of incident DPN cases in the stated population. The target remains human peptidergic C-fibers when a study measures a broader endpoint.

Source assessment

Base judgment: 18.2%; skeptical–optimistic sensitivity: 1.4%–51.7%. Subjective probabilities of the causal proposition below, not effect sizes. Decimal places only show arithmetic. Reviewed 13 September 2026. Probability method · Collection index.

Reasoning from the biological requirements

An axon has a continuous ATP cost even when it is not firing. Lower blood glucose becomes damaging only if it lowers usable local fuel for long enough that alternative substrates, glial delivery and energy reserves cannot meet demand. Electrical silence can conserve energy and can be reversible; therefore conduction failure does not itself establish axon destruction. Repetition could matter by preventing recovery, but several short lows are not automatically equivalent to one prolonged period of near-zero glucose. The physical requirement is a sustained local energy deficit, not the label 'hypoglycemia'.

Probabilities of the necessary claims

Conditional prices are skeptical / base / optimistic. Each price after the first assumes all earlier requirements are true. Their order is an order for assessing joint belief, not necessarily a linear biological pathway. The cumulative column uses the base scenario. Temporal order, connected compartments and the causal prevention comparison are included in these requirements, without extra generic multipliers.

See the claims and probabilities table above.

R1

Blood and interstitial glucose are connected; the exposure distribution at distal human nerve remains uncertain.

R2

Lactate and other substrates provide compensation, so glucose concentration alone cannot settle this.

R3

Severe fuel deprivation can destroy axons, but the human peptidergic threshold is unknown.

R4

Reverse causation and concurrent hyperglycemia complicate human associations; the subgroup must be common enough within this exposure scope.

Evidence that moves the judgment

• Ex vivo sciatic-nerve work found that Schwann-cell glycogen supported myelinated-fiber conduction during glucose withdrawal, with no corresponding glycogen support of C-fiber conduction. It demonstrates a possible reserve asymmetry, not irreversible human C-fiber loss from ordinary brief hypoglycemia. Brown et al., 2012.

• A cross-sectional study included 40 people with diabetes and 28 controls, with four days of CGM. More hypoglycemia was associated with lower corneal nerve branch density. The exposure window is short, the endpoint is corneal rather than distal cutaneous peptidergic structure, and existing neuropathy or disease severity could contribute to both findings. Gad et al., 2022.

• Repeated low/high glucose exposure caused stress and apoptosis in an immortalized mouse Schwann-cell line. This supports a support-cell route under the tested conditions, without determining a human exposure threshold or terminal-loss effect. Kato et al., 2019.

Why these odds and how uncertain they are

Fuel starvation is mechanistically credible, making a near-zero probability inappropriate in a severe-exposure population. The main uncertainty is compensation: many low-glucose episodes end before local energy failure becomes destructive. The human association does not resolve whether hypoglycemia caused the neuropathy, followed autonomic dysfunction, or tracked more difficult diabetes. I therefore give substantially less confidence to the complete structural claim than to glucose deprivation being possible.

The skeptical scenario treats observed CGM lows as brief, buffered events and the association as largely confounded. The optimistic scenario assumes repeated deep episodes exhaust poorly supported distal terminals and recovery between episodes is incomplete. Neither scenario implies that 54 or 70 mg/dL is a universal axon-damage boundary; depth, duration, local delivery and alternative substrates jointly determine exposure.

Conditional inputs: base [85, 55, 65, 60]%; skeptical [65, 25, 35, 25]%; optimistic [95, 80, 85, 80]%. Products give the headline prices. The span measures sensitivity to these interpretations; it is not a statistical confidence interval.

Numerical update example: Public human exposure/structure data showing repeated severe lows precede loss after accounting for baseline neuropathy and average glucose would strengthen the fuel-deficit bridge; evidence of preserved local energetics across those exposures would weaken it. Changing only requirement 2 from 55% to 85% raises the whole price to 28.2%; reducing it to 20% lowers the price to 6.6%. These are hypothetical evidence updates. Even resolving that one requirement with certainty would leave a complete price of 33.1% if the others stayed unchanged.

Overlap and boundary

A specific initiating route into energy failure. Distinct from rapid glycemic correction, which need not include absolute hypoglycemia. Variability asks whether oscillation adds damage beyond mean exposure and low-glucose time.